Global PD-L1 and PIK3CA Testing Market Growth (Status and Outlook) 2025-2031

Global PD-L1 and PIK3CA Testing Market Growth (Status and Outlook) 2025-2031

The global PD-L1 and PIK3CA Testing market size is predicted to grow from US$ 740 million in 2025 to US$ 2366 million in 2031; it is expected to grow at a CAGR of 21.4% from 2025 to 2031.

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.

Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.

PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.

The classification of PD-L1 and PIK3CA Testing Product includes PD-L1 Testing and PIK3CA Testing. PD-L1 accounted for a share of 80% in the global PD-L1 and PIK3CA Testing Product market.

PD-L1 and PIK3CA Testing Product is widely used in Hospital, Diagnostic Center and Other. In PD-L1 and PIK3CA Testing Product market, the Diagnostic Center holds an important share in terms of Application.

North America is the largest consumption place, with a market share nearly 57% . Following North America, Europe is the second largest consumption place with the market share of 28%.

Market competition is intense. Agilent Technologies, Roche, QIAGEN, Amoy Diagnostics, ACCB Biotech, etc. The top five vendors held 84% of the market share.

LPI (LP Information)' newest research report, the “PD-L1 and PIK3CA Testing Industry Forecast” looks at past sales and reviews total world PD-L1 and PIK3CA Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected PD-L1 and PIK3CA Testing sales for 2025 through 2031. With PD-L1 and PIK3CA Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PD-L1 and PIK3CA Testing industry.

This Insight Report provides a comprehensive analysis of the global PD-L1 and PIK3CA Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on PD-L1 and PIK3CA Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PD-L1 and PIK3CA Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PD-L1 and PIK3CA Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PD-L1 and PIK3CA Testing.

This report presents a comprehensive overview, market shares, and growth opportunities of PD-L1 and PIK3CA Testing market by product type, application, key players and key regions and countries.

Segmentation by Type:
PD-L1 Testing
PIK3CA Testing

Segmentation by Application:
Hospital
Diagnostic Center
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Agilent Technologies
Roche
QIAGEN
EntroGen
Amoy Diagnostics
ACCB Biotech

Please note: The report will take approximately 2 business days to prepare and deliver. Show more